Machina Capital S.A.S. Buys 10,751 Shares of Intuitive Surgical, Inc. $ISRG

Machina Capital S.A.S. boosted its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 279.7% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 14,595 shares of the medical equipment provider’s stock after purchasing an additional 10,751 shares during the period. Intuitive Surgical accounts for approximately 1.1% of Machina Capital S.A.S.’s portfolio, making the stock its 7th biggest position. Machina Capital S.A.S.’s holdings in Intuitive Surgical were worth $6,527,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in shares of Intuitive Surgical by 2.1% during the 2nd quarter. Vanguard Group Inc. now owns 33,335,833 shares of the medical equipment provider’s stock worth $18,115,025,000 after purchasing an additional 670,302 shares during the last quarter. State Street Corp increased its position in Intuitive Surgical by 1.2% during the second quarter. State Street Corp now owns 15,552,203 shares of the medical equipment provider’s stock worth $8,451,223,000 after buying an additional 182,871 shares during the last quarter. Geode Capital Management LLC raised its holdings in Intuitive Surgical by 1.4% during the second quarter. Geode Capital Management LLC now owns 8,188,685 shares of the medical equipment provider’s stock valued at $4,429,590,000 after buying an additional 109,904 shares in the last quarter. Norges Bank acquired a new stake in shares of Intuitive Surgical in the second quarter worth about $2,569,260,000. Finally, Invesco Ltd. boosted its stake in shares of Intuitive Surgical by 4.8% during the 2nd quarter. Invesco Ltd. now owns 4,421,133 shares of the medical equipment provider’s stock worth $2,402,488,000 after acquiring an additional 201,159 shares in the last quarter. 83.64% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. Hsbc Global Res raised Intuitive Surgical to a “strong-buy” rating in a research report on Thursday, October 23rd. Robert W. Baird decreased their price objective on shares of Intuitive Surgical from $655.00 to $645.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. Jefferies Financial Group lifted their target price on shares of Intuitive Surgical from $550.00 to $560.00 and gave the stock a “hold” rating in a report on Wednesday, October 22nd. The Goldman Sachs Group reissued a “buy” rating and set a $714.00 target price on shares of Intuitive Surgical in a research report on Friday, January 9th. Finally, Wells Fargo & Company lifted their price objective on Intuitive Surgical from $600.00 to $654.00 and gave the stock an “overweight” rating in a research note on Friday, December 12th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $620.41.

Intuitive Surgical Price Performance

Shares of Intuitive Surgical stock opened at $478.88 on Wednesday. Intuitive Surgical, Inc. has a 52-week low of $425.00 and a 52-week high of $609.08. The firm has a market capitalization of $171.67 billion, a PE ratio of 60.69, a price-to-earnings-growth ratio of 3.86 and a beta of 1.65. The company’s fifty day moving average price is $555.20 and its two-hundred day moving average price is $511.20.

Intuitive Surgical (NASDAQ:ISRG) last posted its earnings results on Thursday, January 22nd. The medical equipment provider reported $2.53 earnings per share for the quarter, beating analysts’ consensus estimates of $2.27 by $0.26. The business had revenue of $2.87 billion for the quarter, compared to analysts’ expectations of $2.72 billion. Intuitive Surgical had a net margin of 28.38% and a return on equity of 15.06%. The firm’s revenue for the quarter was up 18.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.21 earnings per share. Analysts predict that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current fiscal year.

Insider Activity

In other news, EVP Henry L. Charlton sold 13,731 shares of the business’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $580.00, for a total value of $7,963,980.00. Following the transaction, the executive vice president directly owned 3,056 shares of the company’s stock, valued at $1,772,480. The trade was a 81.80% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Craig H. Barratt sold 750 shares of the stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $580.00, for a total value of $435,000.00. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 73,616 shares of company stock valued at $40,929,575. 0.70% of the stock is owned by company insiders.

Intuitive Surgical Company Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.